Key result
Ivabradine administration improved endothelial function in diastolic and right heart failure patients, reducing the post-ischemia MAT/TT index from 30.4 to 23.3 (P=0.002).
Why the study?
Does oral ivabradine improve endothelial function in patients with diastolic and right heart failure?
Observational (n=15)
Does oral ivabradine improve endothelial function in patients with diastolic and right heart failure?
Absolute Event Rate: 23.3% vs 30.4%
p-value: p=0.002
Ivabradine administration over 6 months significantly improved endothelial function in patients with diastolic and right heart failure.
Supports endothelial benefit in diastolic and right heart failure; hypothesis-generating, requiring RCTs before practice change.
Background. Ivabradine is an If ion current inhibitor that has proved to reduce mortality in patients with systolic heart failure by slowing heart rate without decreasing myocardial contractility. Photoplethysmography is a simple, low-cost optical technique that can evaluate vascular function and detect changes in blood flow, pulse, and swelling of tissular microvascular space. Objective. To evaluate the effect of ivabradine on endothelial function by photoplethysmography in diastolic and right heart failure patients. Methodology. 15 patients were included (mean age of 78.1 ± 9.2 years) with optimally treated diastolic and right heart failure. They underwent photoplethysmography before and after induced ischemia to evaluate the wave blood flow on the finger, using the maximum amplitude time/total time (MAT/TT) index. Two measurements were made before and after oral Ivabradine (mean 12.5 mg a day during 6 months of followup). Results. In the study group, the MAT/TT index was 29.1 ± 2.2 versus 24.3 ± 3.2 (P = 0.05) in basal recording and 30.4 ± 2.1 versus 23.3 ± 2.9 (P = 0.002), before versus after ischemia and before versus after Ivabradine intervention, respectively. Conclusions. Ivabradine administration improves endothelial function (shear stress) in diastolic and right heart failure patients.
No takes yet. Share an insight, caveat, or question.
Orea‐Tejeda et al. (2013) conducted an observational in diastolic and right heart failure (n=15). Ivabradine vs. Baseline (before intervention) was evaluated on maximum amplitude time/total time (MAT/TT) index after induced ischemia (p=0.002). Ivabradine administration improved endothelial function in diastolic and right heart failure patients, reducing the post-ischemia MAT/TT index from 30.4 to 23.3 (P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: